Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
RetinalGenix Technologies Inc. is a company dedicated to research and development within the field of ophthalmology. Its core mission involves devising advanced technologies aimed at detecting, supervising, identifying, and treating a range of visual conditions, including those affecting the eyes and those that could lead to vision loss. Their product lineup features the RetinalGeniX Imaging System, an apparatus for broad-scale retinal imaging and screening that does not require pupil dilation, particularly useful for diabetic patients. Additionally, they offer the RetinalCam, a device designed for real-time retinal monitoring and imaging in a home setting, which includes an alert function for medical practitioners. The company was founded in 2017, with its principal offices located in Petaluma, California. RetinalGenix Technologies Inc. operates as a subsidiary of Sanovas Ophthalmology, LLC.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA.